Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
70.00    0.00 (0.00%)
Bid:
69.00
Ask:
71.00
Spread: 2.00 (2.899%)
Market Cap: £318.58m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Directors Dealings

24 Feb 2014 07:00

RNS Number : 6954A
Avacta Group PLC
24 February 2014
 

24 February 2014

Avacta Group plc

("Avacta" or the "Group")

 

Directors' Dealings

 

The Group announces the following changes to the equity incentives of its Non-Executive Chairman, Trevor Nicholls, and its Chief Operating Officer, Craig Slater.

 

Trevor Nicholls

On his appointment to the Board of Avacta on 2 August 2013, Dr Nicholls was awarded options over 5,454,545 ordinary shares of 0.1p each in the Group ("Ordinary Shares"). In order to pursue best corporate governance practice, the Avacta Board has agreed with Dr Nicholls that 3,500,000 of those options should vest conditional upon Dr Nicholls exercising those options immediately and conditional upon it being agreed by Dr Nicholls that the balance of 1,954,545 options over Ordinary Shares be cancelled with immediate effect. Dr Nicholls has agreed to that conditionality and therefore the options over 3,500,000 Ordinary Shares have vested and Dr Nicholls has exercised his option over those Ordinary Shares. 

 

The exercise price of each option is 0.55 pence per share and, following exercise, Dr Nicholls is now interested in a total of 3,500,000 ordinary shares of 0.1p each in the Group, representing approximately 0.1% of the Group's issued share capital.

 

Dr Nicholls no longer holds any options over ordinary shares in Avacta.

 

Application will be made for the 3,500,000 new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 28 February 2014.

 

The total number of Ordinary Shares in issue following the above issue will be 4,026,051,956 each with voting rights. No Ordinary Shares are held in Treasury.

 

The above figure of 4,026,051,956 shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Group under the FCA's Disclosure and Transparency Rules.

 

Craig Slater

On 21 February 2014, Mr Slater was granted options over 20,000,000 Ordinary Shares pursuant to the Avacta Group Enterprise Management Incentive ("EMI") Scheme. The option exercise price is 1.18p per share and the options vest as follows:

 

- 5,000,000 options over Ordinary Shares vest on 23 December 2014

- 5,000,000 options over Ordinary Shares vest on 23 December 2015

- 5,000,000 options over Ordinary Shares vest on 23 December 2016

- 5,000,000 options over Ordinary Shares vest on 23 December 2017

 

In addition, on 21 February 2014 Mr Slater purchased an interest in 34,082,086 existing Ordinary Shares at a price of 1% of 1.18 pence per share, in accordance with the terms of the Avacta Joint Share Ownership Plan (the "Joint Share Ownership Plan") established on 9 January 2012. This interest is joint with Avacta Group Trustee Limited as trustee for the Avacta Group Employee's Share Trust under the Joint Share Ownership Plan. Following this purchase, Mr Slater has an interest in 34,082,086 Ordinary shares, representing approximately 0.8% of the Group's issued share capital.

 

 

Enquiries:

 

Avacta Group plc

Tel: +44 (0) 844 414 0452

Alastair Smith, Chief Executive Officer

www.avacta.com

Tim Sykes, Chief Financial Officer

Numis Securities Limited

Tel: +44 (0) 207 260 1000

Michael Meade / Freddie Barnfield - Nominated Adviser

www.numiscorp.com

James Black - Corporate Broking

Walbrook PR Ltd

Tel: +44 (0) 20 7933 8780 or avacta@walbrookpr.com

Anna Dunphy

Mob: +44 (0)7876 741 001

Lianne Cawthorne

Mob: +44 (0)7584 391 303

 

 

About Avacta Group plc - www.avacta.com

 

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through three divisions:

 

Avacta Analytical

www.avactaanalytical.com

 

High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development.

Avacta Animal Health

www.avactaanimalhealth.com

 

Veterinary diagnostics reference laboratory, diagnostic kits and newly launched in-clinic blood analyser, Sensipod.

Avacta Life Sciences

www.avactalifesciences.com

 

Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development.

 

Avacta joined AIM in August 2006 and is based in Wetherby, England.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLFFSLFRILFIS
Date   Source Headline
1st Jun 20263:00 pmRNSBlock Listing - Application to AIM
1st Jun 20267:00 amRNSClinical data on AVA6000 in salivary gland cancers
29th May 20267:00 amRNSPosting of Annual Report and Notice of AGM
29th May 20267:00 amRNSBoard Director Changes
19th May 20267:00 amRNSUnaudited Preliminary Full Year 2025 Results
13th May 20267:00 amRNSNotice of Preliminary Results and Presentation
13th May 20267:00 amRNSIssue of Equity and Total Voting Rights
6th May 20267:00 amRNSPre|CISION® payload release vs approved ADCs
28th Apr 20267:00 amRNSBlock Listing Six Monthly Return
21st Apr 20267:00 amRNSAvacta data AACR underline AVA6103 profile
14th Apr 202611:37 amRNS-RChristina Coughlin - In Vivo 2026 Rising Leader
9th Apr 20267:00 amRNSQ1 2026 Business Update
8th Apr 20267:00 amRNS-RAvacta Announces Science Day 2026
31st Mar 20267:00 amRNSFirst patient treated in Phase 1 trial of AVA6103
27th Mar 20267:00 amRNSResult of Oversubscribed Fundraise
26th Mar 20265:16 pmRNSProposed Fundraise to raise approximately £10m
26th Mar 20264:44 pmRNSIssue of Equity
17th Mar 20267:00 amRNS-RPresentations of pre|CISION® Platform Candidates
17th Mar 20267:00 amRNS-RPresentations of pre|CISION® Platform Candidates
16th Mar 20267:00 amRNSPhase 1 study opening for AVA6103
16th Mar 20267:00 amRNSPhase 1 study opening for AVA6103
24th Feb 20267:00 amRNSPreCISION payload delivery advantage over ADC
18th Feb 20267:00 amRNS-RAvacta to Participate in Conference March 2026
9th Feb 20267:00 amRNSAppointment of CSO
3rd Feb 20267:00 amRNSFaridoxorubicin Program Clinical Updates
21st Jan 20267:00 amRNSFDA Clearance of IND Application for AVA6103
20th Jan 20267:01 amRNSYear-end trading update
20th Jan 20267:00 amRNSAppointment of Nominated Adviser & TVR
18th Dec 20257:00 amRNS-RAvacta reports new AVA6103 pharmacology data
17th Dec 20257:00 amRNSFaridoxorubicin Phase 1b SGC data
8th Dec 20257:00 amRNSPreliminary Data in Faridoxorubicin Phase 1b Trial
3rd Nov 20258:24 amRNSCompletion of Placing and TVR
27th Oct 20255:39 pmRNSBlock Listing Six Monthly Return
27th Oct 20257:00 amRNSAvacta presents preclinical data at AACR-NCI-EORTC
23rd Oct 20255:00 pmRNS-RNotice of Investor Presentation
20th Oct 20257:01 amRNSEquity fundraise of £16 million
20th Oct 20257:00 amRNSAvacta Presents Phase 1a Data for Faridoxorubicin
13th Oct 20257:00 amRNSAvacta to present data at EORTC-NCI-AACR
30th Sep 20257:00 amRNSInterim Half Year Results 2025
15th Sep 20257:00 amRNSNotice of Interim Results
9th Sep 20257:00 amRNS-RShortlisted for AIM Awards Technology of the Year
1st Sep 20257:00 amRNSAvacta completes sale of Coris Bioconcept
29th Aug 20257:00 amRNSAmendments to Convertible Bond + equity fundraise
30th Jul 20257:00 amRNSAvacta to Present at ESMO Congress
28th Jul 20257:48 amRNSAgreement to Sell Coris Bioconcept SRL
21st Jul 20257:00 amRNSPayment of Convertible Bond Installment
17th Jul 20257:00 amRNSEquity fundraise of £3.25 million
2nd Jul 20255:00 pmRNSResult of AGM
2nd Jul 20257:00 amRNSQ2 2025 Business Update
1st Jul 20257:00 amRNSManagement Team Appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.